Subjects with biopsy-proven NAFLD (n=46) | Subjects with 1H-MRS-proven NAFLD (n=445) | |||||
S<2 (n=19) | S≥2 (n=27) | P value | NFS <0.676 (n=305) | NFS ≥0.676 (n=140) | P value | |
Femoral neck | ||||||
T-score | −1.2 (−1.6–−0.3) | −1.4 (−1.9–−0.7) | 0.237 | −1.5 (−2.2–−0.7) | −1.9 (−2.6–−1.2) | <0.001 |
Z-score | 0.1 (−0.5–1.0) | −0.1 (−0.7–0.9) | 0.384 | −0.1 (−0.7–0.6) | −0.1 (−0.8–0.5) | 0.991 |
BMD value | 0.719 (0.667–0.806) | 0.689 (0.643–0.771) | 0.372 | 0.690 (0.609–0.786) | 0.634 (0.580–0.717) | <0.001 |
Femoral troch | ||||||
T-score | −0.4 (−0.8–0.0) | −0.5 (−1.0–0.0) | 0.468 | −0.9 (−1.6–−0.2) | −1.3 (−1.9–−0.7)# | <0.001 |
Z-score | 0.6 (0.1–0.7) | 0.3 (−0.2–1) | 0.541 | −0.0 (−0.5–0.8) | −0.1 (−0.6–0.5)## | 0.376 |
BMD value | 0.668 (0.619–0.697) | 0.652 (0.610–0.705) | 0.639 | 0.613 (0.549–0.682) | 0.570 (0.512–0.631)## | <0.001 |
Femoral inter | ||||||
T-score | 0.3 (−0.4–0.5) | −0.6 (−1.2–0.0)* | 0.018 | −0.7 (−1.4–−0.1) | −1.2 (−1.9–−0.3)# | <0.001 |
Z-score | 0.6 (−0.4–0.8) | 0.1 (−0.3–0.9) | 0.375 | 0.2 (−0.5–0.7) | 0.1 (−0.6–0.9) | 0.985 |
BMD value | 1.118 (1.007–1.152) | 1.029 (0.913–1.095) | 0.059 | 0.993 (0.892–1.103) | 0.921 (0.830–1.040)# | <0.001 |
Femoral total | ||||||
T-score | −0.2 (−0.9–0.5) | −0.7 (−1.4–−0.1)* | 0.078 | −0.8 (−1.6–−0.2) | −1.4 (−2.1–−0.6) | <0.001 |
Z-score | 0.6 (−0.5–1.2) | 0.1 (−0.5–1.1)* | 0.093 | 0.2 (−0.5–0.9) | 0.2 (−0.5–0.8)# | 0.582 |
BMD value | 0.921 (0.834–1.012) | 0.865 (0.769–0.932)* | 0.090 | 0.846 (0.761–0.935) | 0.779 (0.705–0.869)# | <0.001 |
Lumbar total | ||||||
T-score | −1.3 (−1.7–−0.2) | −0.9 (−1.9–−0.3) | 0.747 | −1.5 (−2.3–−0.5) | −1.6 (−2.6–−0.4) | 0.380 |
Z-score | −0.2 (−1.7–−0.2) | 0.4 (−0.5–0.9) | 0.845 | 0.1 (−0.7–1) | 0.5 (−0.5–1.5) | 0.010 |
BMD value | 0.947 (0.864–1.031) | 0.947 (0.841–1.010) | 0.616 | 0.922 (0.824–1.032) | 0.896 (0.800–1.038) | 0.267 |
*P<0.05 vs S<2, after adjusting for age and BMI; #p<0.05 and ##p<0.01 vs NFS <0.676, after adjusting for age and BMI.
BMD, bone mineral density; BMI, body mass index; 1H-MRS, proton magnetic resonance spectrum; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; S, fibrosis stage in pathology.